Runben Biotechnology (603193) AVIC Securities·2025-06-06 09:16Investment Rating - The investment rating for the company is "Buy" with an expectation of over 10% return relative to the CSI 300 index in the next six months [11]. Core Views - The company is positioned as a leader in the life care sector, focusing on mosquito repellent and baby care products, with a diversified product line enhancing market competitiveness [5]. - The company achieved a revenue of 1.318 billion yuan in 2024, representing a year-on-year growth of 27.61%, and a net profit of 300 million yuan, up 32.80% year-on-year [5][7]. - The online sales channel has shown significant growth, particularly on platforms like Douyin, contributing to the overall revenue increase [5][7]. - The company is expected to maintain steady growth due to product innovation and channel optimization, with projected net profits of 372 million yuan, 481 million yuan, and 615 million yuan for 2025, 2026, and 2027 respectively [7][9]. Summary by Sections Company Overview - Founded in 2006, the company aims to become a global leader in life and personal care products, offering a range of items including mosquito repellent and baby care products [5]. - The company has established a broad sales network both domestically and internationally, with a strong online presence [5]. Financial Performance - In 2024, the company reported a revenue of 1.318 billion yuan, a 27.61% increase from the previous year, and a net profit of 300 million yuan, reflecting a 32.80% growth [5][9]. - The quarterly revenue breakdown for 2024 shows significant growth, particularly in Q2 and Q4, with Q4 net profit experiencing some fluctuations due to increased promotional expenses [5][7]. Product Performance - The mosquito repellent product line generated 439 million yuan in revenue in 2024, a 35.39% increase, with a gross margin improvement to 54.18% [7]. - The baby care product line achieved 690 million yuan in revenue, up 32.42%, with a gross margin of 59.81% [7]. Channel Strategy - The online sales channel contributed 970 million yuan in revenue, a 23.80% increase, while non-platform distribution revenue reached 347 million yuan, growing by 39.64% [7]. - The company is enhancing its collaboration with e-commerce platforms to optimize its market presence and improve gross margins [7]. Future Projections - The company forecasts continued revenue growth, with expected revenues of 1.710 billion yuan, 2.131 billion yuan, and 2.530 billion yuan for 2025, 2026, and 2027 respectively [9]. - The projected net profit for the next three years indicates a robust growth trajectory, with EPS expected to rise from 0.92 yuan in 2025 to 1.52 yuan in 2027 [9].